Borregaard (BRG) Pre-close call summary
Event summary combining transcript, slides, and related documents.
Pre-close call summary
19 Mar, 2026Executive summary
Sales volumes for BioSolutions expected at 340,000 tonnes for 2026, with growth in agriculture; Q1 volume in line with prior year at 80,000 tonnes.
BioMaterials sales forecast at 155,000-160,000 tonnes in 2026, up from 146,000 tonnes in 2025; specialized grades to see slight growth.
Fine Chemicals sales prices for bioethanol expected to remain stable; intermediates volume to increase.
Trading performance and revenue trends
BioSolutions growth driven by agriculture, but construction and oilfield chemicals markets remain weak.
BioMaterials average sales price expected to decline 3%-4% in H1 2026 due to product/customer mix and selective price adjustments.
Additional 4,000-5,000 tonnes to be sold in 2026 due to prior production disruption.
Profitability and margins
EBITDA for BioSolutions in 2025 not much stronger than 2024 due to increased costs, especially at U.S. plants and above-inflation cost rises.
Wood costs expected to be 15% lower in H1 2026 versus H1 2025, partially offsetting higher energy costs.
Latest events from Borregaard
- Q2 revenues and cash flow rose, but Alginor impairment and higher costs hit profit.BRG
Q2 202622 Jul 2026 - Specialisation, sustainability, and innovation fuel growth in high-value bio-based markets.BRG
Corporate presentation20 Jul 2026 - Sales volumes steady, but cost inflation and market uncertainty drive focus on cost controls.BRG
Pre-close call16 Jun 2026 - EBITDA fell 16% year-over-year as cost inflation and weaker BioSolutions weighed on results.BRG
Q1 202629 Apr 2026 - Specialisation, innovation, and sustainability drive growth and strong financial performance.BRG
Company presentation29 Apr 2026 - Specialisation, sustainability, and innovation drive growth and value in advanced biorefinery markets.BRG
Corporate presentation29 Apr 2026 - AGM approved a 12% dividend increase, board renewal, and strong financial and sustainability plans.BRG
AGM 202624 Apr 2026 - Record EBITDA, strong cash flow, higher dividend, and start-up impairments define the period.BRG
Q4 20254 Feb 2026 - BioSolutions strength offset weaker BioMaterials; outlook cautious amid rising costs.BRG
Q2 20243 Feb 2026